Harmony Biosciences spotlights Phase 3 HBS-301 narcolepsy, idiopathic hypersomnia studies at SLEEP 2026

Harmony

HRMY

0.00

Harmony Biosciences flagged six narcolepsy or idiopathic hypersomnia abstracts slated for poster presentation at the SLEEP 2026 meeting on June 14-17.
Future presentations include analyses of pitolisant in narcolepsy subgroups, sleep-pattern effects in idiopathic hypersomnia, and long-term safety and effectiveness in idiopathic hypersomnia.
Upcoming posters also outline Phase 3, placebo-controlled studies of HBS-301 in narcolepsy or idiopathic hypersomnia, signaling continued pipeline investment beyond pitolisant.
No trial outcomes were disclosed in the announcement; results are set to be presented during poster sessions on June 15-16.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harmony Biosciences Holdings Inc. published the original content used to generate this news brief on June 11, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.